Dr Doug Wilson has done an excellent job of telling us a lot without revealing any of the details.
"Some of the most exciting successes of the Company are commercially sensitive to our clients," said Wilson.
So, what did we find out?
Well, it appears that Roche are intensifying their independent research into the peptide candidates put forward by Phylogica. Wilson conveys the impression that Roche see the potential for the "cell-penetrating peptides" to be "more widely applied".
Getting drugs into cells is the next pharmaceutical frontier The latest investor presentation boldly proclaims that Big Pharma Wants IN. Roche happens to be at the front of the queue.
The collaboration with the University of Cambridge is another commercial-in-confidence teaser.
"There are intense ongoing discussions with the prestigious UK cancer research unit the MRC Hutchison Institute at the University of Cambridge where our collaboration has been growing over the past three years and where exciting commercial opportunities are in discussion," said Wilson.
According to the accompanying notes in the latest Appendix 4C, "Phylogica's Directors anticipate additional income before the end of the current quarter based on a successful outcome from one or more of the Company's numerous revenue opportunities." The clock is ticking towards a major re-rating of Julia Lee's small cap star for 2011.
PYC Price at posting:
7.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)